| Ytd | 208.16% | |
| 1y | 164.91% |
| Open | 2.65 | Prev Close | 2.70 | Low | 2.64 | High | 3.11 | Mkt Cap | 352.01M |
| Vol | 5.86M | Avg Vol | 3.80M | EPS | -1.09 | P/E | N/A | Forward P/E | -0.99 |
| Beta | 1.88 | Short Ratio | 3.10 | Inst. Own | 102.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 2.02 | 200-d Avg | 1.40 | 1yr Est | 6.31 |
FATE News
SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-sta
HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Bu
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.26) per share which beat the analys
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Fate Therapeutics will present clinical and translational data from the systemic lupus erythematosus
HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to brin
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to bring
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which missed the anal
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twel
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analys
HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutra
Wedbush analyst David Nierengarten upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Outpe
As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-sev
Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and l
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.29) per share which beat the analys
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lup
Barclays analyst Peter Lawson maintains Fate Therapeutics (NASDAQ:FATE) with a Overweight and low
Baird analyst Jack Allen maintains Fate Therapeutics (NASDAQ:FATE) with a Neutral and lowers the
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.32) per share which beat the analys
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Wednesday.
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly ear
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
Friday's session saw 169 companies set new 52-week lows.
Friday's session saw 225 companies set new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
On Tuesday, 210 companies reached new 52-week lows.
During Monday's session, 201 stocks hit new 52-week lows.
During the Friday's sesion, 157 stocks hit new 52-week lows.
On Thursday, 128 companies set new 52-week lows.
Companies Reporting Before The Bell • Warner Music Gr (NASDAQ:WMG) is likely to report quarterly ea
During Thursday's session, 92 stocks hit new 52-week lows.
During Wednesday's trading, 103 companies set new 52-week lows.
On Tuesday, 46 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the co